Key Insights

Highlights

Success Rate

83% trial completion

Published Results

44 trials with published results (23%)

Research Maturity

82 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

8.8%

17 terminated out of 193 trials

Success Rate

82.8%

-3.7% vs benchmark

Late-Stage Pipeline

22%

42 trials in Phase 3/4

Results Transparency

54%

44 of 82 completed with results

Key Signals

44 with results83% success17 terminated

Data Visualizations

Phase Distribution

160Total
Not Applicable (39)
Early P 1 (6)
P 1 (14)
P 2 (59)
P 3 (20)
P 4 (22)

Trial Status

Completed82
Unknown35
Recruiting27
Terminated17
Active Not Recruiting13
Not Yet Recruiting10

Trial Success Rate

82.8%

Benchmark: 86.6%

Based on 82 completed trials

Clinical Trials (193)

Showing 20 of 20 trials
NCT07533006Phase 2RecruitingPrimary

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

NCT07749716Phase 2Not Yet RecruitingPrimary

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

NCT07029204Early Phase 1Active Not RecruitingPrimary

Intralesional Cyclosporine for Alopecia Areata

NCT07748169Recruiting

An Observational Study of Patients With Dermatologic Disease

NCT06012240Phase 3RecruitingPrimary

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT07023302Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

NCT07733063Recruiting

Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata

NCT07733765Phase 3Not Yet RecruitingPrimary

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

NCT06531109RecruitingPrimary

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT07617597Phase 3RecruitingPrimary

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

NCT07705217Not ApplicableNot Yet RecruitingPrimary

The Role of Gut and Skin Microbiota in Alopecia Areata

NCT06340360Phase 2Active Not RecruitingPrimary

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

NCT07696585Not ApplicableNot Yet RecruitingPrimary

New Topical Treatment in Patchy Alopecia Areata

NCT06602232Phase 1Active Not RecruitingPrimary

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

NCT06747611Phase 2RecruitingPrimary

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT05398809Phase 2Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

NCT03976622Enrolling By Invitation

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

NCT05551793Phase 2RecruitingPrimary

Regeneron AA Multicenter (Dupilumab)

NCT07645430Not ApplicableCompletedPrimary

Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.

NCT06444451Phase 2TerminatedPrimary

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Scroll to load more

Research Network

Activity Timeline